Brensocatib, an investigational first‐in‐class, small‐molecule, orally bioavailable, selective, and reversible dipeptidyl peptidase 1 inhibitor that blocks activation of neutrophil serine proteases, is currently under clinical development for the treatment of bronchiectasis and other chronic inflammatory diseases. The gene discussed is CTSC; the disease is bronchiectasis.